New cell therapy tested for tough blood cancers
Disease control
Terminated
This early-stage study tested a new cell therapy called CNTY-101 in 28 patients with relapsed or hard-to-treat B-cell blood cancers. The main goals were to find a safe dose and see how the body processes the treatment. The study was terminated early, and it focused on patients wh…
Phase: PHASE1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC